Holly Buckley

Yeah, we agree.

Yeah, thank you for that opportunity. We're super excited. As you said, May 14th and 15th in Chicago. Anyone's welcome to reach out to me if they have questions. We've got a packed agenda with kind of deep dive sessions on healthcare provider investments, pharma services, digital health, as well as management of portfolio companies.

Yeah, thank you for that opportunity. We're super excited. As you said, May 14th and 15th in Chicago. Anyone's welcome to reach out to me if they have questions. We've got a packed agenda with kind of deep dive sessions on healthcare provider investments, pharma services, digital health, as well as management of portfolio companies.

We have a portfolio company boot camp on the 13th leading into the conference. It's a pre-conference event. And we have some great keynote panels, including Lance Armstrong. And we have a healthcare leadership panel on the 14th, as well as healthcare private equity and healthcare lending keynote panels as well. So the content is going to be great. The networking opportunities will be even better.

We have a portfolio company boot camp on the 13th leading into the conference. It's a pre-conference event. And we have some great keynote panels, including Lance Armstrong. And we have a healthcare leadership panel on the 14th, as well as healthcare private equity and healthcare lending keynote panels as well. So the content is going to be great. The networking opportunities will be even better.

And we'd love to see folks who are interested attending and reach out to me at hbuckley at mcguirewoods.com if you have questions.

And we'd love to see folks who are interested attending and reach out to me at hbuckley at mcguirewoods.com if you have questions.

Thank you, Scott.

Thank you, Scott.

Yeah, Scott, thanks. And thanks as always for having me on. I have three topics to talk about today. The first one is on semaglutide, which is the ingredient used in diet drugs such as Wegovy and Zetbound. And the FDA determined at the end of last month, on February 21st, that there's no longer a shortage of semaglutide medications. Now, what this means is that it's come off the shortage list.

Yeah, Scott, thanks. And thanks as always for having me on. I have three topics to talk about today. The first one is on semaglutide, which is the ingredient used in diet drugs such as Wegovy and Zetbound. And the FDA determined at the end of last month, on February 21st, that there's no longer a shortage of semaglutide medications. Now, what this means is that it's come off the shortage list.

And so compounders cannot compound that drug. And so all of these alternatives to agovian Zetbound that have kind of proliferated on the market that are compounded are no longer able to be made. And the FDA has said it will not take action against those compounders. until April for state-licensed pharmacy or physician compounders or May 22nd for outsourcing facilities that are 503B facilities.

And so compounders cannot compound that drug. And so all of these alternatives to agovian Zetbound that have kind of proliferated on the market that are compounded are no longer able to be made. And the FDA has said it will not take action against those compounders. until April for state-licensed pharmacy or physician compounders or May 22nd for outsourcing facilities that are 503B facilities.

But after that point, the FDA may go after them if they are still compounding semaglutide. And so we're also likely to see an increase in cease and desist letters from manufacturers, such as Eli Lilly and Novo Nordisk, who make SCOBY and ZetBound they may well start to go after more of the compounders if they continue to compound.

But after that point, the FDA may go after them if they are still compounding semaglutide. And so we're also likely to see an increase in cease and desist letters from manufacturers, such as Eli Lilly and Novo Nordisk, who make SCOBY and ZetBound they may well start to go after more of the compounders if they continue to compound.

That's right. That's right. So because there was a shortage, the FDA kind of put the drug on a shortage list. It meant these compounders could do what they otherwise would not have been able to do. You're right. It was a leeway that they wouldn't normally have. And that leeway is now gone. And so it'll be interesting to see.

That's right. That's right. So because there was a shortage, the FDA kind of put the drug on a shortage list. It meant these compounders could do what they otherwise would not have been able to do. You're right. It was a leeway that they wouldn't normally have. And that leeway is now gone. And so it'll be interesting to see.

A lot of those companies are saying that they're going to pursue other opportunities. But there was kind of a huge market for them that it turned out, is pretty short-lived, right? A lot of them really proliferated in 2024 and now will likely have to do something different.

A lot of those companies are saying that they're going to pursue other opportunities. But there was kind of a huge market for them that it turned out, is pretty short-lived, right? A lot of them really proliferated in 2024 and now will likely have to do something different.

Yeah, so this is a continuation of something we've talked about a number of other times, and it is this, I'll use the word proliferation again, proliferation of states that are passing healthcare transaction notice laws. And last time we chatted, we talked about California and they had the big veto of the 3129 bill last year. They've come back this year with a couple of different bills.